Cargando…
Targeting ADAM10 in Cancer and Autoimmunity
Generating inhibitors for A Disintegrin And Metalloproteinase 10 (ADAM10), a zinc-dependent protease, was heavily invested in by the pharmaceutical industry starting over 20 years ago. There has been much enthusiasm in basic research for these inhibitors, with a multitude of studies generating signi...
Autores principales: | Smith, Timothy M., Tharakan, Anuj, Martin, Rebecca K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105615/ https://www.ncbi.nlm.nih.gov/pubmed/32265938 http://dx.doi.org/10.3389/fimmu.2020.00499 |
Ejemplares similares
-
Editorial: ADAM10 in Cancer Immunology and Autoimmunity: More Than a Simple Biochemical Scissor
por: Rossello, Armando, et al.
Publicado: (2020) -
Role of ADAM10 and ADAM17 in the Regulation of Keratinocyte Adhesion in Pemphigus Vulgaris
por: Kugelmann, Daniela, et al.
Publicado: (2022) -
Modulation of Immune Responses by Platelet-Derived ADAM10
por: Maurer, Stefanie, et al.
Publicado: (2020) -
Assessment of ADAM17 and ADAM10 proteins with CXCL10 and thyroid autoimmunity in vitiligo pathogenesis
por: Kılıc, Sevilay, et al.
Publicado: (2022) -
Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma
por: Hansen, Hinrich P., et al.
Publicado: (2020)